---
title: "CervoMed Climbs 5% on USPTO Neflamapimod Patent Approval for DLB"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290234344.md"
description: "CervoMed rose 5% to $4.01 after USPTO approved neflamapimod patent for DLB treatment through 2042."
datetime: "2026-06-18T18:13:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290234344.md)
  - [en](https://longbridge.com/en/news/290234344.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290234344.md)
---

# CervoMed Climbs 5% on USPTO Neflamapimod Patent Approval for DLB

CervoMed(CRVO.US) 盘中涨超**5%**，现报**4.011**美元。

美国专利商标局（USPTO）批准该公司 neflamapimod 用于治疗纯路易体痴呆症（DLB）患者的专利，专利保护期延长至 2042 年。该专利针对不伴有显著阿尔茨海默病样 tau 病理的 DLB 患者群体。

公司宣布进行 1000 万美元的注册直接普通股发行，每股定价 4.00 美元，所得款项将用于营运资金和一般企业用途。

### Related Stocks

- [CRVO.US](https://longbridge.com/en/quote/CRVO.US.md)

## Related News & Research

- [Cervo posts investor presentation on website covering clinical, development and financial updates](https://longbridge.com/en/news/289829022.md)
- [CervoMed Posts Updated Investor Presentation and Business Overview](https://longbridge.com/en/news/289834335.md)
- [CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | CRVO Stock News](https://longbridge.com/en/news/290228255.md)
- [Roth MKM Reaffirms Their Buy Rating on CervoMed (CRVO)](https://longbridge.com/en/news/289519604.md)
- [CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | CRVO Stock News](https://longbridge.com/en/news/289591456.md)